Press Releases Bayer AG

Equities

BAYN

DE000BAY0017

Pharmaceuticals

Market Closed - Xetra Other stock markets 16:38:50 20/01/2026 GMT			After hours 20:59:57
42.92 ^EUR	-3.34%		42.86	-0.13%

04:57pm	DAX Index Extends Losing Streak; German Economic Sentiment Improves	MT
03:16pm	Illumina Secures Reimbursement of Nearly $3,000 Per TruSight Test	MT

Press Releases

12:32pm	Bayer Aktiengesellschaft: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution	EQ
07:30am	Bayer and Vanderbilt University Medical Center to Advance Treatments for Cardiovascular and Kidney Diseases	BU
01-16	Bayer welcomes the U.S. Supreme Court decision to review the Durnell case in the Roundup™ litigation	BU
01-16	Bayer : welcomes the U.S. Supreme Court decision to review the Durnell case in the Roundup™ litigation	PU
01-16	Bayer : Eylea™ 8 mg approved in the EU for third retinal indication	PU
01-13	Bayer Accelerates Pharma Growth on High-Value Portfolio	BU
01-13	Actress and Menopause Advocate Gabrielle Union-Wade Partners with Bayer in the Lynkuet® (elinzanetant) ‘Life Doesn’t Stop for a Hot Flash’ Campaign for Moderate to Severe Hot Flashes Due to Menopause	BU
01-12	Bayer to Expand Into Molecular Imaging With Acquisition of Innovative Pan-Amyloid Radiotracers From Attralus	BU
01-12	Bayer : to expand into molecular imaging with acquisition of innovative pan-amyloid radiotracers from Attralus	PU
01-08	Bayer : to launch innovative strawberry variety	PU
01-08	Bayer and Soufflé Therapeutics Announce Strategic Collaboration to Advance Cell-Specific Heart-Targeted siRNA Therapy	BU
01-06	Bayer : receives Breakthrough Therapy Designation in the U.S. and China for sevabertinib as a first-line treatment for patients with HER2-mutant non-small cell lung cancer	PU
01-05	Bayer to Present Updates on Pharma Growth Strategy and Pipeline Advancements at J.P. Morgan’s 44th Annual Healthcare Conference	BU
01-05	Bayer : to present updates on pharma growth strategy and pipeline advancements at J.P. Morgan’s 44th Annual Healthcare Conference	PU
12-29	Bayer Aktiengesellschaft: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution	EQ
12-22	Bayer : Finerenone approved in Japan for treatment of patients with chronic heart failure	PU
12-19	Bayer Aktiengesellschaft: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution	EQ
12-19	Bayer Aktiengesellschaft: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution	EQ
12-12	Bayer : Aflibercept 8 mg recommended for EU approval for third retinal indication	PU
12-09	Bayer : AskBio’s AB-1005 and AB-1002 Receive Pioneering Regenerative Medical Product Designation in Japan	PU
12-05	Bayer Aktiengesellschaft: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution	EQ
12-04	Bayer Aktiengesellschaft: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution	EQ
12-04	Bayer : MediaBayer starts Phase IIa study for treatment of patients with Alport Syndrome	PU
12-04	Bayer Starts Phase IIa Study for Treatment of Patients With Alport Syndrome	BU
12-03	RSNA25: Pediatric Study for Bayer's Investigational MRI Contrast Agent Gadoquatrane Meets Primary and Secondary Endpoints	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies Trading Ideas

Filters

Headlines

Bayer slows after strong recovery, valuation stretched

December 17, 2025 at 08:41 am

Bayer, close to the final round(up)?

June 05, 2025 at 03:56 pm

Roundup: Bayer ordered to pay $2.1bn to an American suffering from cancer

March 24, 2025 at 10:21 am